Loic Vincent

Company: Affini-T Therapeutics

Job title: Chief Scientific Officer

Seminars:

Pre-Clinical Development of Safe & Effective T Cell Receptor-Engineered CD4+ & CD8+ T Cell Therapies Specific for Mutant KRAS 10:00 am

Advantages of TCR-engineered CD4+ and CD8+ T cell therapies to induce deep and durable anti-tumor responses against KRas mutant tumors Preclinical data of TCR-engineered T cell therapies targeting KRas mutant tumors Synthetic biology strategy for boosting TCR-engineered T cell trafficking and persistence in the hostile TME of KRas mutant tumors to ensure durable responsesRead more

day: Day Two